Co-Diagnostics, Inc 8-K, filed Oct 15, 2026
Co-Diagnostics, Inc. (CODX)
About this 8-K
Co-Diagnostics, Inc filed this 8-K on October 15, 2026, reporting on events of October 14, 2026.
Co-Diagnostics, Inc. could not conduct business at its reconvened October 14, 2026 Annual Meeting because no quorum was present, ended the meeting without another adjournment, and plans to seek stockholder approval at a future special meeting. AI summary
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). Because a quorum was not present or represented, the Company was unable to transact business at the Annual Meeting. The Annual Meeting was subsequently adjourned and reconvened on September 24, 2026 and September 30, 2026, but a quorum was not present or represented on either date. The Annual Meeting was therefore adjourned again to October 14, 2026.
On October 14, 2026, the Company reconvened the Annual Meeting. A quorum was not present or represented, and the Company was therefore unable to transact business at the Annual Meeting. The Company determined not to adjourn the Annual Meeting again.
The Company currently intends to seek stockholder approval of the proposals that were to be considered at the Annual Meeting at a special meeting of stockholders to be held on a future date. If the Company proceeds with such special meeting, the Company will announce the date, time and location of the special meeting and provide additional information regarding the special meeting and the matters to be considered thereat in proxy materials to be filed with the Securities and Exchange Commission and distributed to the Company’s stockholders.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| CO-DIAGNOSTICS, INC. | ||
| Date: October 15, 2026 | By: | /s/ Dwight Egan |
| Name: | Dwight Egan | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||